VSee Health (VSEE) Co-CEO receives four 2025 stock grants

Rhea-AI Filing Summary

Aisiku Imoigele reported acquisition or exercise transactions in this Form 4 filing.

VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported receiving four quarterly equity awards of common stock under the company’s 2024 Incentive Plan, all dated March 23, 2026 and tied to 2025 quarters. The grants cover 128,342 shares at $0.37 per share, 78,689 shares at $0.61, 41,379 shares at $1.16, and 40,000 shares at $1.20, issued as stock compensation pursuant to his executive employment agreement.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aisiku Imoigele

(Last) (First) (Middle)

C/O VSEE HEALTH, INC.

980 N FEDERAL HWY #304

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VSEE HEALTH, INC. [ VSEE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	03/23/2026		A		128,342	A	$0.37(1)	3,545,031	D
Common Stock, par value $0.0001 per share	03/23/2026		A		78,689	A	$0.61(2)	3,416,689	D
Common Stock, par value $0.0001 per share	03/23/2026		A		41,379	A	$1.16(3)	3,338,000	D
Common Stock, par value $0.0001 per share	03/23/2026		A		40,000	A	$1.2(4)	3,296,621	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan (the "Incentive Plan") as the quarterly equity award owed by the issuer to the reporting person for the quarter ended December 31, 2025 pursuant to the Executive Employment Agreement between the reporting person and the issuer dated December 10, 2025 (the "Employment Agreement"). The number of shares issued to the reporting person is based on the closing price of the common stock on December 31, 2025.

2. Reflects shares of common stock issued to the reporting person under the Incentive Plan as the quarterly equity award owed by the issuer to the reporting person for the quarter ended September 30, 2025 pursuant to the Employment Agreement. The number of shares issued to the reporting person is based on the closing price of the common stock on September 30, 2025.

3. Reflects shares of common stock issued to the reporting person under the Incentive Plan as the quarterly equity award owed by the issuer to the reporting person for the quarter ended June 30, 2025 pursuant to the Employment Agreement. The number of shares issued to the reporting person is based on the closing price of the common stock on June 30, 2025.

4. Reflects shares of common stock issued to the reporting person under the Incentive Plan as the quarterly equity award owed by the issuer to the reporting person for the quarter ended March 31, 2025 pursuant to the Employment Agreement. The number of shares issued to the reporting person is based on the closing price of the common stock on March 31, 2025.

	/s/ Imoigele Aisiku	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did VSEE Co-CEO Aisiku Imoigele report on this Form 4?

Co-CEO Aisiku Imoigele reported receiving four grants of VSee Health common stock as equity compensation. These stock awards were issued under the 2024 Incentive Plan as quarterly equity grants owed for 2025 under his executive employment agreement.

How many VSEE shares were granted to Aisiku Imoigele and at what prices?

The filing shows four stock grants: 128,342 shares at $0.37, 78,689 shares at $0.61, 41,379 shares at $1.16, and 40,000 shares at $1.20. Each grant involves common stock with a par value of $0.0001 per share.

What is the purpose of the VSEE stock grants disclosed for Aisiku Imoigele?

The grants represent quarterly equity awards owed to Aisiku Imoigele for each quarter of 2025. They are issued under VSee Health’s 2024 Incentive Plan pursuant to his executive employment agreement, functioning as part of his stock-based compensation package.

Which periods do the VSEE equity awards to Aisiku Imoigele relate to?

Footnotes explain the stock was issued as quarterly equity awards for the quarters ended March 31, June 30, September 30, and December 31, 2025. Each quarter’s award is based on the closing price of VSee Health common stock on the respective quarter-end date.

Were Aisiku Imoigele’s VSEE stock grants open-market purchases or compensation awards?

They were compensation awards, not open-market purchases. The transactions are coded “A” for grants or awards and are described as quarterly equity awards under the 2024 Incentive Plan, issued pursuant to Aisiku Imoigele’s executive employment agreement with VSee Health.

Does the VSEE Form 4 indicate any stock sales by Aisiku Imoigele?

No stock sales are reported in this Form 4 excerpt. All listed transactions are coded as acquisitions via grants or awards of common stock, reflecting equity compensation rather than dispositions or open-market sales by Co-CEO and director Aisiku Imoigele.